ERBB2 and small cell lung carcinoma: In addition, downstream KRAS, BRAF and other activation mutations, HER2 mutation, MET amplification lead to bypass activation, PTEN lost, and transformation to small-cell lung cancer (SCLC), which are also the mechanisms of acquired drug resistance.